Clarissa Sowemimo-Coker, CEO of Oxford Cannabinoid Technologies Holdings, discusses with Proactive’s Thomas Warner the successful completion of a phase 1 clinical trial for its lead drug candidate OCT461201.
This groundbreaking compound is aimed at addressing chemotherapy-induced peripheral neuropathy (CIPN), a debilitating condition that affects a significant portion of chemotherapy patients.
Phase 1 success
Proactive: Congratulations on the successful phase 1 clinical trial for OCT461201. Can you tell us more about this milestone and the significance of the compound?
Sowemimo-Coker: Thank you! We're thrilled to have achieved this milestone. OCT461201 is our most advanced compound and has been a focal point of discussion over the past year.
This phase 1 clinical trial, conducted in collaboration with Simbec-Orion, tested the compound on healthy volunteers with the final dose administered on September 20th.
The primary objective was to assess the safety and tolerability of the compound.
We're pleased to report that the trial was a success with no adverse events.
It's important to note that while this compound interacts with a cannabinoid receptor in the human body, it's technically not a cannabinoid but a new chemical entity.
Next steps for OCT461201
Proactive: What are the next steps for OCT461201 and what role does the Pharmacokinetics (PK) data play in its development?
Sowemimo-Coker: Our next steps involve working closely with our Chief Medical Officer, Tim Cole, and our Chief Scientific Officer, Valentino Pribetic.
We'll be engaging with our Scientific Advisory Board and specialist advisors to plan the compound's further development.
The PK data collected from the phase 1 trial provides us with valuable insights into the drug's performance in the body, helping us refine our approach.
This trial's success is a pivotal milestone in advancing the development of OCT461201.
CIPN impact
Proactive: What can you share about the target condition, chemotherapy-induced peripheral neuropathy (CIPN) and the potential impact of OCT461201 on patients?
Sowemimo-Coker: CIPN is a debilitating condition that affects approximately 60% of patients who undergo chemotherapy.
Currently, there are no effective treatments available for this condition. OCT461201 offers hope as a potential solution for those patients living with CIPN.
It's a significant problem to solve, and we're excited to be one step closer to providing a new treatment option for these individuals.
Next steps for OCT
Proactive: What can investors and the public expect from Oxford Cannabinoid Technologies in the upcoming months, especially leading up to the end of the year?
Sowemimo-Coker: We'll continue to provide updates on the progress of OCT461201 and our other ongoing programs. While I can't give away all our plans, you can expect more news on our developments in the near future.
We're committed to advancing our mission of bringing innovative solutions to patients in need.
In summary, OCT461201’s phase 1 trial represents a significant step forward in addressing chemotherapy-induced peripheral neuropathy (CIPN).
The compound's safety and tolerability have been demonstrated, and the company is now focused on the next stages of development.
As OCT continues to work towards providing new treatment options for patients, updates on their progress can be expected in the coming months.